Procter & Gamble Health Ltd

₹ 6,287 1.29%

12 Jun - close price

About

P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.^[1]

Key Points

Strong Brand Portfolio
Company is one the India’s largest VMS companies, manufacturing and marketing vitamins, minerals and supplements. It has a strong portfolio of various pharma brands such as Evion, Neurobion, Seven seas, Nasivion, Polybion, Cosome and Livogen. ^[1]

Website BSE NSE

Market Cap ₹ 10,436 Cr.
Current Price ₹ 6,287
High / Low ₹ 6,739 / 4,700
Stock P/E 31.9
Book Value ₹ 316
Dividend Yield 1.99 %
ROCE 83.5 %
ROE 61.6 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company has a good return on equity (ROE) track record: 3 Years ROE 42.5%
Company has been maintaining a healthy dividend payout of 123%

Cons

Stock is trading at 19.9 times its book value
The company has delivered a poor sales growth of 0.76% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Figures in Rs. Crores

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	321	301	305	310	252	284	313	310	311	339	325	374	370
	241	256	216	208	185	236	199	186	230	248	205	263	235
Operating Profit	80	45	89	102	67	48	114	123	81	90	120	110	136
OPM %	25%	15%	29%	33%	27%	17%	36%	40%	26%	27%	37%	30%	37%
	5	5	6	5	2	-18	3	4	3	4	5	4	4
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	6	6	6	7	7	7	6	6	5	5	6	6	6
Profit before tax	79	44	88	100	63	23	111	122	79	89	119	109	133
Tax %	25%	32%	26%	28%	26%	26%	26%	25%	22%	25%	26%	29%	29%
	59	30	66	72	47	17	82	91	61	66	89	78	95
EPS in Rs	35.66	17.96	39.50	43.42	28.05	10.11	49.60	54.76	36.86	39.87	53.34	46.74	56.99
Raw PDF

Profit & Loss

Figures in Rs. Crores

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Jun 2020 18m	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Mar 2025 9m	Mar 2026
	940	993	698	849	927	1,356	1,009	1,114	1,230	1,151	934	1,408
	855	877	621	701	723	1,037	762	846	905	845	616	951
Operating Profit	85	116	77	148	204	319	246	268	325	307	319	457
OPM %	9%	12%	11%	17%	22%	24%	24%	24%	26%	27%	34%	32%
	22	24	74	768	48	66	18	13	18	-5	10	17
Interest	0	0	0	0	0	0	1	0	1	1	0	1
Depreciation	23	25	19	21	17	29	30	27	28	27	17	24
Profit before tax	83	115	132	895	234	355	233	253	314	273	312	450
Tax %	36%	31%	29%	6%	32%	28%	24%	24%	27%	26%	25%	27%
	54	79	94	839	159	254	177	193	229	201	234	327
EPS in Rs	32.27	47.67	56.57	505.27	95.64	153.07	106.51	115.98	138.24	121.08	141.22	196.94
Dividend Payout %	23%	23%	27%	87%	0%	150%	122%	45%	69%	215%	89%	211%

Compounded Sales Growth
10 Years:	4%
5 Years:	1%
3 Years:	8%
TTM:	51%

Compounded Profit Growth
10 Years:	20%
5 Years:	5%
3 Years:	19%
TTM:	39%

Stock Price CAGR
10 Years:	25%
5 Years:	2%
3 Years:	7%
1 Year:	8%

Return on Equity
10 Years:	31%
5 Years:	35%
3 Years:	43%
Last Year:	62%

Balance Sheet

Figures in Rs. Crores

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Mar 2025	Mar 2026
Equity Capital	17	17	17	17	17	17	17	17	17	17	17	17
Reserves	575	647	717	1,524	800	890	687	600	734	522	520	508
	0	0	0	0	0	0	8	3	12	10	8	9
	192	215	258	219	250	269	275	269	338	247	250	308
Total Liabilities	784	879	991	1,759	1,067	1,176	986	888	1,101	794	794	841
	132	111	115	104	101	101	104	112	144	128	116	102
CWIP	7	30	9	17	11	21	39	41	32	6	11	14
Investments	42	28	70	0	0	0	0	0	0	0	0	0
	603	711	797	1,639	954	1,053	843	736	925	660	667	726
Total Assets	784	879	991	1,759	1,067	1,176	986	888	1,101	794	794	841

Cash Flows

Figures in Rs. Crores

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Mar 2025	Mar 2026
	83	107	54	-130	235	247	170	236	228	169	338
	-68	-75	-48	1,270	165	-32	-26	-22	-7	10	1
	-12	-15	-22	-30	-883	-387	-289	-98	-418	-235	-344
Net Cash Flow	4	17	-16	1,109	-483	-172	-145	116	-197	-56	-5
Free Cash Flow	38	75	24	-157	212	196	132	198	207	168	323
CFO/OP	136%	138%	147%	117%	106%	128%	87%	100%	102%	78%	97%

Ratios

Figures in Rs. Crores

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Mar 2025	Mar 2026
Debtor Days	49	39	64	28	30	26	22	27	34	27	57	43
Inventory Days	140	145	243	154	139	113	138	124	136	120	152	137
Days Payable	55	67	128	124	106	105	209	185	239	184	239	192
Cash Conversion Cycle	134	118	179	58	63	34	-49	-34	-69	-37	-30	-13
Working Capital Days	69	52	94	42	22	23	7	17	15	19	48	30
ROCE %	15%	18%	16%	78%	20%	29%	29%	38%	45%	45%	48%	84%

Insights

In beta

Dec 2014

Dec 2015

Dec 2017

Dec 2018

Jun 2020

Jun 2021

Jun 2022

Mar 2024

Mar 2025

Injectable Production Capacity (Goa Plant)
Million units per annum

xxx.xx	xxx.xx	xxx.xx		xx.xx	xx.xx	xx.xx	x.xx	x.xx
x,xxx	x,xxx		x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx
			x,xxx				xx,xxx	xxx,xxx
							xx,xxx	xx,xxx
				xxx,xxx				xxx,xxx
							xxx,xxx	xxx,xxx
							xxx,xxx	x,xxx,xxx
								xx
x.xx		x.xx	x.xx	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Total Employees
Number

Healthcare Practitioners (HCPs) Engaged
Number

Direct Rural Reach
Number of towns

Pharmacy Reach (Neurobion)
Number of stores

Total Pharmacy Reach
Number of stores

Total Retail Outlet Coverage
Number of outlets

Productivity Savings
INR Crores

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%
	7.15%	7.38%	7.60%	6.24%	6.39%	6.61%	7.01%	6.86%	6.99%	7.24%	6.97%	6.20%
	12.29%	12.30%	12.66%	13.72%	14.56%	14.84%	14.71%	14.21%	14.15%	13.90%	13.84%	13.67%
	28.74%	28.50%	27.92%	28.22%	27.24%	26.74%	26.47%	27.11%	27.03%	27.05%	27.37%	28.30%
No. of Shareholders	58,856	57,919	56,730	56,778	55,923	54,792	53,736	53,993	52,478	50,006	49,302	50,883

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	51.80%	51.80%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%
	2.28%	3.66%	4.24%	4.62%	6.71%	6.57%	6.72%	6.24%	6.86%	6.20%
	10.07%	9.59%	7.42%	10.39%	11.48%	7.91%	12.31%	13.72%	14.21%	13.67%
	35.85%	34.95%	36.53%	33.17%	30.00%	33.71%	29.14%	28.22%	27.11%	28.30%
No. of Shareholders	31,699	28,556	32,142	45,514	53,076	66,289	61,030	56,778	53,993	50,883

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls